New anti-VEGF agents for wet age-related macular degeneration can extend injection intervals to 3-5 months but may increase ...

June 30, 2025, expected to fund planned operations into 2028 EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage ...

D-150 Phase 3 program in wet AMD advancing ahead of plan, with expected 4FRONT-1 data readout accelerated to H1 2027 from H2 2027 and 4FRONT-2 initiated ahead of schedulePresented positive 60-week res ...

Second-Quarter 2025 and Recent Selected Highlights: <li /> Total revenues of $63.7 million, a 30% increase over $48.

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

EyePoint Pharmaceuticals completed enrollment in the LUCIA trial, its second phase 3 trial of Duravyu in patients with wet ...

Q2 2025 Earnings Call Transcript August 5, 2025 Ocular Therapeutix, Inc. misses on earnings expectations. Reported EPS is $-0 ...

A groundbreaking study titled "An Engineered Intravitreal Injection Retinal-Pigment-Epithelium-Tropic Adeno-Associated Virus ...

LONG BEACH, Calif. -- Depletion of a payment assistance program has translated into worse vision outcomes for older patients ...

Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized – – LUGANO and LUCIA ...

Gain insights into EyePoint Pharmaceuticals' Q2 2025 performance, featuring DURAVYU's Phase III progress in wet-AMD, global expansion, and ...